因此从原则上来说,IBD达标治疗(STRIDE-II)提供了一个巨大的机会,即使不能彻底治愈疾病也可以长期控制疾病,但在CD和UC治疗的临床实践中仍需要分别探讨。 尤其需要基于患者预后、高危因素、严重程度进行分层,根据STRIDE-II设置不同的治疗目...
Inflammatory bowel disease (IBD) outreach monitoring has been shown to be cost-effective and reduce healthcare utilization. IBD STRIDE-II guidelines recommend monitoring patient-reported outcomes (PRO's), biomarkers (e.g., fecal calprotectin (FCP), C-reactive protein (CRP)), and endoscopy to ...
2015年由国际炎症性肠病组织(IOIBD)发起讨论并投票达成的炎症性肠病治疗目标选择(STRIDE)共识明确了以T2T为理念的成人IBD治疗目标。2021年更新的STRIDE-Ⅱ推荐旨在更好地解决IBD复杂性及其对受累患者生活多方面的影响,包括首次纳入了儿童和青少年IBD患者。STRIDE-II提出了更系统更深层次的IBD治疗目标,不仅考虑典型的IBD...
Results: A total of 332 pediatric IBD patients fulfilled the inclusi on criteria of which 143 (43 %) were diagnosed with Crohn's di sease (CD), 147 (44.2 %) with ulcerative colitis (UC) and 42 (12.6 %) with IBD-unclassified (IBD-u). In total, 51 (15.3 %) ...
Plain language summary: Best practice suggestions for incorporating STRIDE-II into UK clinical practice for the management of patients with Crohn's disease Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) characterised by endoscopic inflammation and damage, estim...
本文总结了“达标治疗(T2T)”策略在STRIDE-Ⅱ共识到临床实践发展过程中面临的机遇及需克服的挑战,以便在日常临床实践中建立STRIDE-II定义的治疗目标,并进一步完善“T2T”的概念。 一、IBD治疗目标:达标治疗(T2T)的概念 在前生物制剂时代,治疗目标主要局限于控制症状、减少激素使用和避免手术,如今已经扩展到以患者为中心...